MMAI

5-Methoxy-6-methyl-2-aminoindane (MMAI) CAS # 132980-16-6


Product Description

5-Methoxy-6-methyl-2-aminoindane (MMAI), is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non-neurotoxic and highly selective serotonin releasing agent (SSRA) and produces entactogen effects in humans. It has been sold as a designer drug and research chemical online since 2010.

MMAI has been shown to relieve stress-induced depression in rats more robustly than sertraline, and as a result it has been suggested that SSRAs like MMAI and 4-MTA could be developed as novel antidepressants with a faster onset of therapeutic action and superior efficacy to current antidepressants such as the selective serotonin reuptake inhibitors (SSRIs).

Reviews

There are no reviews yet.

Be the first to review “5-Methoxy-6-methyl-2-aminoindane (MMAI) CAS # 132980-16-6”